Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Operations (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Cash from Operations for 14 consecutive years, with 11699000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 30.37% year-over-year to 11699000.0, compared with a TTM value of 14170000.0 through Dec 2025, up 79.92%, and an annual FY2025 reading of 19272000.0, up 75.53% over the prior year.
  • Cash from Operations was 11699000.0 for Q4 2025 at Enanta Pharmaceuticals, down from 6489000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 17506000.0 in Q2 2025 and bottomed at 35641000.0 in Q4 2022.
  • Average Cash from Operations over 5 years is 17638850.0, with a median of 16167500.0 recorded in 2022.
  • The sharpest move saw Cash from Operations crashed 557.44% in 2021, then soared 218.48% in 2025.
  • Year by year, Cash from Operations stood at 13271000.0 in 2021, then crashed by 168.56% to 35641000.0 in 2022, then increased by 29.89% to 24988000.0 in 2023, then soared by 32.76% to 16801000.0 in 2024, then surged by 30.37% to 11699000.0 in 2025.
  • Business Quant data shows Cash from Operations for ENTA at 11699000.0 in Q4 2025, 6489000.0 in Q3 2025, and 17506000.0 in Q2 2025.